To the Editor: In Seol et al, 1 the authors provide a clinicopathologic analysis showing that intratumoral heterogeneity of HER2 gene amplification is associated with short disease-free survival. They conclude that it is likely that intratumoral heterogeneity is a surrogate for chromosomal instability, and thus a poor prognosis. This result would appear directly to conflict with the study of Bartlett et al, 2 showing that patients with tumors that are uniformly HER2-amplified do worse than those with heterogeneity (eg, 30-50% of cells with a ratio 42.2). Seol et al 1 attribute this difference to a variation in study design-that they have selected their heterogeneous cases from tumors that were already classified as HER2-amplified on whole-tissue sections. To this reader, an alternative interpretation presents itself, which takes into account patient treatment, as well as one study 3 not cited by Seol et al (See Table 1 ). From Table 1 , it appears that intratumoral heterogeneity, in and of itself, is not a poor prognostic marker at all. 2 Rather, high/unequivocal HER2 amplification is a favorable predictor of response to (antracyclinebased) chemotherapy-a result that has been well documented. 3, 4 Moreover, patients with low-HER2-amplification-and heterogeneity, perhaps-still benefit from trastuzumab in addition to chemotherapy. 1, 3 Seol et al 1 rightly highlight the importance of determining the HER2 amplification status accurately, both overall and taking into account intratumoral heterogeneity. Based on our own work, a fully satisfactory definition of heterogeneity has not been forthcoming. A persistent problem is how to distinguish bonafide heterogeneity from statistical artifact. 5 Both Bartlett et al 2 and Seol et al 1 raise the possibility of examining 'regional heterogeneity'. The current guidelines address this by recommending that distinct (clustered) To the editor: We read with great interest the comments by Arena et al. and Chang in reference to our paper, 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'. 1 Their letters focused on different issues of the HER2 intratumoral heterogeneity in breast cancer. Arena et al. questioned about the best way to write HER2 reports for the clinician and suggested that HER2 analytical report should be completed with a critical evaluation of the results about HER2 genetic heterogeneity. Although the clinical relevance of HER2 genetic heterogeneity is not established in breast cancer, we agree that HER2 in situ hybridization report should include not only overall average ratio of HER2/CEP17 and average HER2 gene copy number, but also information about HER2 genetic heterogeneity. However, there are some issues to be addressed in the definition of HER2 genetic heterogeneity proposed by 2009 College of American Pathologists expert panel, which indicates the presence of tumor cells with HER2/CEP17 signal ratios 42.2 (or 46 HER2 signals per cell when using a probe for HER2 only) in 5-50% of the tumor cells tested. 2 If 20 cells are counted and 1 tumor cell is identified with a HER2/CEP17 42.2, the tumor is diagnosed to have HER2 genetic heterogeneity. However, a recent study revealed that the tumor cells with 3:1 HER2/CEP17 ratio, which may reflect technical issues, were determining factor for heterogeneity in 46% of heterogeneous cases. 3 Furthermore, Allison et al. 4 reported that the ratio criteria and the criteria based on HER2 signals per cell for definition of HER2 genetic heterogeneity were not equivalent and the ratio-based definition resulted in large numbers of non-amplified cases being classified as heterogeneous. Thus, to avoid artifactual heterogeneity caused by technical issues, such as nuclear truncation and inadequate hybridization, cutoff values of percentage and cell ratio for HER2 genetic heterogeneity need to be validated. Furthermore, the number of cells to be counted and the fields to be selected for counting should be clearly defined through robust evidence.
HER2 intratumoral heterogeneity appears as two forms; distinct clusters of amplified cells and admixture of amplified and non-amplified cells. Distinct HER2 amplified clones in a non-amplified tumor, which was defined as HER2 regional heterogeneity in our study, should be scored separately, as proposed previously. 2,5 HER2 regional heterogeneity can be assessed by scanning the entire tumor section before selection of fields to be counted and matching with HER2 immunohistochemistry (IHC). If the tumor has differentially amplified or stained area, the regions should be included in the counting. From this point of view, silver in situ hybridization has an advantage to evaluate HER2 regional
